Nrx Pharmaceuticals shares rise 3.17% premarket after FDA granted designation for NRX-100, expanding addressable population.

Nrx Pharmaceuticals, Inc. rose 3.17% in premarket trading, following the news that the company has been granted FDA designation for NRX-100, expanding its addressable population to 13 million Americans who consider suicide each year. This designation represents a 10x expansion compared to the 2017 designation for bipolar depression alone and includes an FDA determination that NRX-100 has the potential to address an unmet need, which is a requirement for a Commissioner's National Priority Voucher (CNPV) program.